findmyKOL
Clinical trialNCT02535312Active, not recruitingPhase 1/PHASE2Interventional

Methoxyamine, Cisplatin, and Pemetrexed Disodium in Treating Patients With Advanced Solid Tumors or Mesothelioma That Cannot Be Removed by Surgery or Mesothelioma That Is Refractory to Pemetrexed Disodium and Cisplatin or Carboplatin

SponsorNational Cancer Institute (NCI)Enrollment30Advanced Malignant Solid NeoplasmAdvanced Peritoneal Malignant MesotheliomaAdvanced Pleural Malignant MesotheliomaRecurrent Peritoneal Malignant MesotheliomaRecurrent Pleural Malignant MesotheliomaRefractory Malignant Solid Neoplasm+1 more conditions
View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This phase I/II trial studies the side effects and the best dose of methoxyamine when given together with cisplatin and pemetrexed disodium and to see how well it works in treating patients with solid tumors or mesothelioma that have spread to other places in the body and usually cannot be cured or controlled with standard treatment (advanced), or mesothelioma that does not respond to pemetrexed disodium and cisplatin or carboplatin (refractory). Methoxyamine may shrink the tumor and may also help cisplatin and pemetrexed disodium work better by making tumor cells more sensitive to the drugs. Drugs used in chemotherapy, such as cisplatin and pemetrexed disodium, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving methoxyamine together with cisplatin and pemetrexed disodium may be a better treatment for solid tumors or mesothelioma than methoxyamine and pemetrexed disodium.

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

14 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States
  • City of Hope Comprehensive Cancer Center

    Duarte, California, United States

  • Los Angeles General Medical Center

    Los Angeles, California, United States

  • Usc / Norris Comprehensive Cancer Center

    Los Angeles, California, United States

  • Keck Medical Center of Usc Pasadena

    Pasadena, California, United States

  • University of California Davis Comprehensive Cancer Center

    Sacramento, California, United States

  • Uchealth University of Colorado Hospital

    Aurora, Colorado, United States

  • University of Maryland/greenebaum Cancer Center

    Baltimore, Maryland, United States

  • University of Michigan Rogel Cancer Center

    Ann Arbor, Michigan, United States

  • Mayo Clinic in Rochester

    Rochester, Minnesota, United States

  • Ohio State University Comprehensive Cancer Center

    Columbus, Ohio, United States

  • Upmc Hillman Cancer Center

    Pittsburgh, Pennsylvania, United States

  • Vanderbilt Breast Center at One Hundred Oaks

    Nashville, Tennessee, United States

  • Vanderbilt University/ingram Cancer Center

    Nashville, Tennessee, United States

  • University of Wisconsin Carbone Cancer Center - University Hospital

    Madison, Wisconsin, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
8 Mar 2016
Primary completion
31 Dec 2022
Completion
15 Oct 2026
Last update posted
31 Jul 2026
Registered enrollment
30
Registry id
NCT02535312

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.